Use of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs)
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) represent a breakthrough in anemia treatment, especially for chronic kidney disease (CKD) patients. These drugs are transforming the anemia drugs market, as outlined in the Anemia Drugs Market report. HIF-PHIs work by stabilizing hypoxia-inducible factors, which regulate erythropoietin production and iron metabolism.
Unlike traditional erythropoiesis-stimulating agents (ESAs), which directly inject synthetic erythropoietin, HIF-PHIs enhance the body’s natural ability to produce erythropoietin under low oxygen conditions. This oral therapy offers a convenient alternative to injectable ESAs.
Clinical trials demonstrate that HIF-PHIs effectively increase hemoglobin levels and improve iron utilization with potentially fewer cardiovascular side effects. Their dual action on erythropoiesis and iron regulation addresses anemia’s multifactorial causes in CKD.
The approval of drugs like roxadustat and daprodustat marks a significant step forward. HIF-PHIs also hold promise for treating anemia related to inflammation and other chronic diseases.